7-methoxy-1-methyl-3,4-dihydro-2H-pyrido[3,4-b]indole

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 7-methoxy-1-methyl-3,4-dihydro-2H-pyrido[3,4-b]indole
• 化学式: C₁₃H₁₄N₂O
• 分子量: 214.267
• InChiKey: QJOZJXNKVMFAET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.15
• 重原子数：
  16.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  33.62
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-丁烯酰氯 、 7-methoxy-1-methyl-3,4-dihydro-2H-pyrido[3,4-b]indole 在 吡啶 、 水 作用下， 生成 (E)-But-2-enoic acid [2-(2-acetyl-6-methoxy-1H-indol-3-yl)-ethyl]-amide
  参考文献：
  名称：

  Begum, Sabira; Usmani, Shahid Bader; Siddiqui, Bina Shaheen, Arzneimittel-Forschung/Drug Research, 1996, vol. 46, # 12, p. 1163 - 1168

  摘要：

  DOI：

文献信息

• Combination therapy for dementia, depression and apathy
  申请人：Sheldon James Leslie

  公开号：US20060287299A1

  公开（公告）日：2006-12-21

  The invention provides, in part, methods and compositions for treating psychiatric disorders, for example, apathy, dementia, or depression, using combination therapies such a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor in combination with an anti-psychotic agent.

  本发明提供了治疗精神障碍的方法和组合物，例如，使用单胺氧化酶抑制剂或选择性血清素再摄取抑制剂与抗精神病药物等组合疗法治疗无动于衷、痴呆或抑郁等精神障碍。
• THERAPEUTIC AGENTS AND USES THEREOF
  申请人：Ankh Life Sciences Limited

  公开号：US20220033417A1

  公开（公告）日：2022-02-03

  Human therapeutic compositions are provided, comprising compounds including a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compounds are the reaction products of aldehyde and harmaline components. The compositions exhibit anti-cancer properties, especially against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

  提供了人类治疗组合物，其中包括具有多个融合多环基团和连接基团的化合物。在某些实施例中，这些化合物是醛和哈马林组分的反应产物。该组合物表现出抗癌性质，特别是对淋巴瘤、白血病、胰腺癌、子宫内膜癌、卵巢癌、胃癌、乳腺癌、肾癌、宫颈癌、头颈癌和骨髓瘤细胞系。
• Thymoquinone/harmaline and related reaction products
  申请人：Ankh Life Sciences Limited

  公开号：US10875859B2

  公开（公告）日：2020-12-29

  New compositions of matter useful for the treatment of human diabetes and cancers comprise the reaction products of thymoquinone and harmaline or harmaline-like compounds, such as β-carboline compounds, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds.

  可用于治疗人类糖尿病和癌症的新物质组合物包括胸腺醌和禾草灵或禾草灵类化合物（如β-咔啉化合物）的反应产物，以及此类化合物的衍生物、溶剂、原药、异构体和同系物。
• Molecular sensors and uses thereof
  申请人：New York University

  公开号：US11242555B2

  公开（公告）日：2022-02-08

  The present disclosure provides molecular sensors. The molecular sensors may be flexible or linear and are oligonucleotide-based and have fluorescent groups. The molecular sensors may be used in methods to measure molecular crowding, identify of binding modes of various substrates, pharmaceutical drug screens, and in high-throughput methods.

  本公开提供分子传感器。分子传感器可以是柔性或线性的，以寡核苷酸为基础并带有荧光基团。分子传感器可用于测量分子拥挤度、识别各种底物的结合模式、药物筛选和高通量方法。
• Low-temperature synthesis of thymoquinone and harmaline compounds
  申请人：Ankh Life Sciences Limited

  公开号：US11358963B2

  公开（公告）日：2022-06-14

  Low-temperature syntheses of thymoquinone/harmaline compounds are provided which give increased yields of desirable products having molecular weights of from about 360-380. The syntheses involve carrying out reactions between thymoquinone and harmaline and a non-interfering solvent at a temperature of less than about 10° C.

  本发明提供了胸腺醌/禾草灵化合物的低温合成方法，可提高分子量约为 360-380 的理想产品的产量。这些合成涉及在低于约 10°C 的温度下进行胸腺醌和禾草灵与无干扰溶剂之间的反应。